Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

Withdrawn before enrolling · Phase 3

Conditions studied: Back Pain

In brief

1. To show that patients with greater pain sensitivity will show greater improvement in their symptoms (self-reported pain intensity, mood, sleep, and quality of life) than those with lower pain sensitivity, based on QST, after taking milnacipran. 2. To compare outcome differences (pain intensity, mood, activity interference, sleep, and side effects) with those patients who are either taking or not taking opioids for their pain 10 weeks after being prescribed milnacipran. 3. To show that patients who are older, male, with more medical comorbidities, greater disability, and longer pain duration will report less improvement (pain, mood, sleep, health-related quality of life) and treatment satisfaction while taking milnacipran compared with others without such characteristics.

Key facts

Study ID

NCT01221740

Run by

Brigham and Women's Hospital

People needed

0

Starts

2010-08-01

Expected to finish

2011-08-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Primary diagnosis of spinal pain for at least 6 months' duration
• Average pain intensity score of 4 or greater

You may not qualify if…

• Current diagnosis of cancer or malignant disease
• Acute bone disease
• History of DSM-IV psychotic disorder
• Pregnancy
• Any illness judged by the PI to interfere with treatment
• Any acute condition requiring surgery
• Currently taking SNRI or MAOI

Where it is running

• Brigham and Women's Hospital Pain Trials Center — Chestnut Hill, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.